ClinicalTrials.gg
Active, not recruitingNCT06706310Updated Sep 11, 2026

Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection

A Phase 2 interventional study of Placebo and TQA3334 Tablet in Chronic Hepatitis B, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active, not recruiting at 15 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited — 4 open to participants now, 6 under way, 1 of them phase 3. Hepatitis B, Chronic · Sino Biopharmaceutical Limited.

Enrollment
7th of 13
116 · median 116
Started
2024
with 2 others
Phase 2
4 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, this one is the 7th largest by enrollment, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 11th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

4 of the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This study uses random, double -blindness, placebo control, and phase multi -center test design. All subjects who meet the standards receive TQ-A3334 per tablet/placebo nucleoside (acid) analog. A total of 116 subjects are needed.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Those who meet all the selected standards below can enter the group test:

  • The subject can communicate well with the researchers and understand and comply with the various items in this study, understand and sign the consent of ;
  • 18-65 years old (including the boundary value), and men and women are not limited (calculated based on the date of signing the consent of informedness);
  • Serum virus standard: serum HBSAG positive for more than 6 months or more than 6 months chronic Evidence of infection.
  • No obvious liver cirrhosis is judged by researchers;

Those who have been treated after treatment need to meet the following conditions:

  • The subject must receive oral nucleoside (acid) drug treatment before screening ≥6 months and the stable treatment plan before the screening period is ≥3 months;
  • Historian history records of the HBV DNA \<6 and above HBV DNA \<6) HBV DNA \<minimum detection lower limit.

The initial governance subjects need to meet the following conditions:

  • If the preliminary governance subject does not have HBSAG positive for 6 months, researchers can make the knot according to the initial diagnosis Fruit, the clinical manifestations of the subjects, and the comprehensive judgment of the family history of hepatitis B family whether it is chronic infection;
  • The subjects have never received the treatment of chronic hepatitis B antiviral treatment (oral nucleoside drugs and interferon) at the time of screening;
  • The reference value (ULN) \<≤ 5 × ULN (within 2 weeks before the first medication)

Exclusion criteria

Exclusion Criteria:

Anyone who appears below will not be able to enter the group test:

  • Pregnancy (pregnancy test is positive) or lactating women.
  • Combined other virus infections such as hepatitis A virus, virus, hepatitis D virus, hepatitis E virus, , syphilis (those with positive syphilis antibodies, and those who are judged by researchers) and so on.
  • History of liver cirrhosis or before screening/screening shows significant fibrosis or liver cirrhosis; or abdominal ultrasound examination prompts suspected liver cirrhosis; past liver dysfunction history or screening period has liver dysfunction compensation For those such as ascites, hepatic brain diseases, and esophageal stomach veins, bleeding;
  • The subject of Hepatocellular Carcinoma (HCC) before screening or at the time of screening has a history of Hepatocellular Carcinoma (HCC), or suspected HCC;
  • There is a history of malignant tumor diseases within the first 5 years of screening. Except for specific menstrual resection, it can be completely cured (such as skin basal cell carcinoma, etc.).
  • A subject with other chronic liver diseases, including but not limited to liver disease, alcoholic liver disease, hepatolenticular degeneration, etc.
  • Organization and bone marrow transplantation have been accepted in the past.
  • Poor thyroid disease, or clinical thyroid dysfunction (TSH abnormal T3 or T4 abnormalities);
  • Eye disease: Including the bottom of the eye lesions (changes in the cotton samples with symptoms of the eye) and retinal lesions.
  • Autoimmune diseases include but are not limited to: systemic lupus erythematosus, rheumatoid arthritis, etc.
  • In addition to liver disease, there are obvious systemic or major diseases.
  • Any systemic anti -tumor (including radiation) or treatment (including biomorphic inhibitors), or immunotherapies within 6 months before screening.
  • Blood transfusion within ≤ 2 months before screening and/or donate blood within 1 month before screening. Note: The subject must not donate blood during the entire study;
  • History of allergies to test medicines or its auxiliary materials;
  • Toll-like receptors-7, Toll-like receptors-8 receptor agonist or , PD-L1 similar drugs have been used within three months before screening.
  • The subject has participated in a clinical trial and accepted the test medicine for the test before the first time of the administration: 5 semi -half -life (such as known) or studying the duration of the biological effects (such as such as the duration of the biological effects (such as such as the duration of the biological effects (such as such as the duration of the biological effects (such as such as the duration of the biological effects (such as such as the duration of the biological effects (such as such as the duration of the biological effects (such as the duration of the biological effects (such as the duration of the biological effects (such as the duration of the biological effects (such as Two times (known) or 90 days (if the elderly prevails) or 90 days (if the half -life or duration is unknown).
  • History or condition of cardiovascular disease: History of risk factors for risk factors of cutting -out rooms, including miracles, known long syndrome, heart failure, myocardial infarction, angina pectoris, or clinical significance laboratory Examination (including hypokalemia, hypercalcemia, or hypomagnesemia). Long QT syndrome or BRUGADA syndrome family history. shows abnormal clinical significance. Heart rate≤45 Secondary/minutes.
  • Researchers believe that those should not be included.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Active comparator
    TQ-A3334 tablets 0.2mg quaque die (QD), combined with nucleoside (acid) analogs (NAs)

    TQA3334 tablets 0.2mg once a day 0.2 mg/time, 1 time/night, 48 weeks of administration; 1 time/day for combined medication, 72 weeks of administration; 72 weeks.

    Drug: TQA3334 Tablet · Drug: Nucleoside (acid) analogs (NAs)

  • Placebo comparator
    0.2mg quaque die (QD) placebo, combined with nucleoside (acid) analogs (NAs)

    Placebo tablets 0.2mg once a day,0.2 mg/time, 1 time/night, 48 weeks of administration; 1 time/day for combined medication, 72 weeks of administration; 72 weeks.

    Drug: Placebo · Drug: Nucleoside (acid) analogs (NAs)

  • Active comparator
    TQ-A3334 tablets 0.5mg once the next day(QOD), combined with nucleoside (acid) analogs (NAs)

    TQA333 tablets 0.5mg once the next day once the next day, administration for 48 weeks; combined medication 1/day, 72 weeks of administration.

    Drug: TQA3334 Tablet · Drug: Nucleoside (acid) analogs (NAs)

  • Placebo comparator
    Placebo 0.5mg once the next day (QOD) , combined with nucleoside (acid) analogs (NAs)

    Placebo 0.5mg once the next day, administration for 48 weeks; combined medication 1/day, 72 weeks of administration;

    Drug: Placebo · Drug: Nucleoside (acid) analogs (NAs)

  • Active comparator
    TQ-A3334 tablets 0.5mg quaque die (QD), combined with nucleoside (acid) analogs (NAs)

    TQA3334 tablets 0.5mg once a day, 1/night, 48 weeks of administration; 1 time/day for combined medication, 72 weeks of administration; 72 weeks.

    Drug: TQA3334 Tablet · Drug: Nucleoside (acid) analogs (NAs)

  • Placebo comparator
    Placebo 0.5mg quaque die (QD) combined with nucleoside (acid) analogs (NAs)

    Placebo 0.5mg once a day, 1/night, 48 weeks of administration; 1 time/day for combined medication, 72 weeks of administration; 72 weeks.

    Drug: Placebo · Drug: Nucleoside (acid) analogs (NAs)

Interventions

06

What researchers measure

Primary outcomes

  1. At 24 weeks, the changes in serum HBSAG relative to the baseline

    Evaluate the subject of chronic HBV infection in the early treatment/treatment of chronic HBV infection, TQ-A3334 combined with oral nucleoside (acid) drugs comparative placebo and oral nucleoside (acid) drugs, can it significantly improve the treatment for 24 weeks Serum HBSAG relative to the changes in the baseline

    Time frame: Up to 24 weeks

Secondary outcomes

  1. The incidence of adverse events(AEs)

    To investigate the incidence of adverse events (AEs) during treatment

    Time frame: Up to 48 weeks

  2. Severity of adverse events (AEs)

    To study the severity of adverse events (AEs) during treatment

    Time frame: Up to 48 weeks

  3. Incidence of serious adverse events (SAEs)

    To investigate the incidence of serious adverse events (SAEs) during treatment

    Time frame: Up to 48 weeks

  4. Severity of serious adverse events(SAEs)

    To investigate the severity of serious adverse events (SAEs) during treatment

    Time frame: Up to 28 weeks

  5. HBsAg<100 IU/ml and HBV DNA <20 IU/ml subject

    The proportion of subjects of HBsAg\<100 IU/ml and HBV DNA \<20 IU/ml.

    Time frame: Week 24, 48 weeks, 60 weeks, 72 weeks

  6. HBSAG self -based lines drop ≥0.5, ≥1 Log10IU/ml

    Awarded by HBSAG's self -base line decrease ≥0.5, ≥1 Log10IU/ml.

    Time frame: Week 24, 48 weeks, 60 weeks, 72 weeks

  7. The proportion of subjects of HBSAG serological removal and/or serum transformation during the study period

    HBSAG serum science clearance and/or serum transition ratio proportion

    Time frame: Week 24, 48 weeks, 60 weeks, 72 weeks

  8. The proportion of subjects of HBEAG serological removal and/or serum conversion during the study period

    The proportion of subjects of HBEAG serological removal and/or serum transformation during the study.

    Time frame: Week 24, 48 weeks, 60 weeks, 72 weeks

  9. Peak time (Tmax)

    Time to peak blood concentration after a single dose.

    Time frame: Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose

  10. Peak Concentration

    The highest plasma drug concentration that can be achieved after medication.

    Time frame: Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose

  11. Area under blood concentration-time curve (AUC)

    The amount of drug absorbed into the human circulation after a single dose can be estimated using the area under the blood concentration-time curve.

    Time frame: Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose

  12. Apparent volume of distribution (Vd/F)

    When a drug reaches homeostasis in the body, the ratio of the amount of drug in the body to the blood concentration is called the apparent volume of distribution

    Time frame: Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose

  13. Plasma clearance

    How many milliliters of plasma can the kidneys completely clear in unit time (per minute)

    Time frame: Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, D15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, D57 and D85 0hour pre-dose.

  14. Elimination half-life time

    The time it takes for the plasma concentration to drop by half.

    Time frame: Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose

  15. Peaking Time

    The time required to reach peak steady-state concentration after administration.

    Time frame: Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, D15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, D57 and D85 0hour pre-dose.

  16. Steady state maximum concentration

    The highest blood concentration that occurs after stabilization.

    Time frame: Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose

  17. Steady state minimal concentration

    The lowest blood concentration that occurs after stabilization

    Time frame: Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose

  18. Area under steady-state blood concentration-time curve

    After the dosage of a single agent, the amount of dosage of the blood circulation of the person can be used with blood concentration-the area of the area under the time curve.

    Time frame: Day1 0 hour pre-dose,10,20,30minutes,1,2,3,6,12,24,48 hours after dose, Day15 within 60 minutes pre-dose, Day29 0h pre-dose,10, 20, 30 minutes, 1,2,3,6,12,24,48 hours after dose, Day57 and Day85 0hour pre-dose

07

Study locations

15 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Dec 2025, 12 months.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 12 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 26, 2024
StartActual
Dec 4, 2024
Primary completionActual
Dec 7, 2025
CompletionEst.
Dec 2026
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06706310
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Dec 4, 2024
Primary completion
Dec 7, 2025
Completion
Dec 2026 (estimated)
Last update
Sep 11, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TLR7 Agonist JNJ-64794964

Start the discussion